Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer

By sjmartinez • January 27, 2023

Chan A, Ruiz-Borrego M, Marx G, Chien AJ, Rugo HS, Brufsky A, Thirlwell M, Trudeau M, Bose R, García-Sáenz JA, Egle D, Pistilli B, Wassermann J, Cheong KA, Schnappauf B, Semsek D, Singer CF, Foruzan N, DiPrimeo D, McCulloch L, Hurvitz SA, Barcenas CH. Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer. Breast. 2022 Dec 14;67:94-101. doi: 10.1016/j.breast.2022.12.003. Epub ahead of print. PMID: 36702070.

Tags: breast cancer, Diarrhea prophylaxis, Dose escalation, early stage, health-related quality of life, Hematology/Oncology, HER2-positive, Neratinib, Publications, Tyrosine kinase inhibitor

Mitochondrial DNA Fragment Dynamics in Acute and Chronic Human Immunodeficiency Virus: Insights From Human and Nonhuman Primate Models

Sun J, Nidadavolu LS, Hsu HY, Rajagopal RG, Astemborski J, Wu Y, Jiang Y, Sacha JB, Kievit P, Jamieson BD, Roberts CT, Kirk GD, Brown[...]

CDK4/6 Inhibition in the Management of Metastatic HR+/HER2+ Breast Cancer: Systematic Review and Meta-analysis

Park D, Varda M, Yeremian S, Hwang A, Huang C. CDK4/6 Inhibition in the Management of Metastatic HR+/HER2+ Breast Cancer: Systematic Review and Meta-analysis. Target[...]

Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer

Barata PC, Corrigan JK, La J, Culnan JM, Akama-Garren E, Dulberger KN, Dumontier C, Hansen J, Bihn JR, Bitting RL, Brophy MT, Cheng HH, Cooperberg[...]